Alexander Solms

690 total citations
30 papers, 437 citations indexed

About

Alexander Solms is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Alexander Solms has authored 30 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Cardiology and Cardiovascular Medicine and 6 papers in Genetics. Recurrent topics in Alexander Solms's work include Hemophilia Treatment and Research (11 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Alexander Solms is often cited by papers focused on Hemophilia Treatment and Research (11 papers), Atrial Fibrillation Management and Outcomes (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Alexander Solms collaborates with scholars based in Germany, United States and Canada. Alexander Solms's co-authors include Dirk Garmann, Annika Hoyer, Oliver Kuß, Stefan Willmann, Maria Elisa Mancuso, Erik Berntorp, Anita Shah, Liping Zhang, Wilhelm Huisinga and Cédric Hermans and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Kidney International.

In The Last Decade

Alexander Solms

29 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexander Solms Germany	13	188	110	88	58	40	30	437
Rhonda Porche-Sorbet United States	12	124 0.7×	63 0.6×	50 0.6×	21 0.4×	26 0.7×	16	528
Boissel Jp France	8	109 0.6×	38 0.3×	32 0.4×	7 0.1×	16 0.4×	47	323
K. Matthes Germany	11	156 0.8×	49 0.4×	53 0.6×	30 0.5×	6 0.1×	23	309
A P Fletcher United States	5	56 0.3×	71 0.6×	50 0.6×	22 0.4×	15 0.4×	8	304
Tariq Roshan Canada	11	98 0.5×	54 0.5×	80 0.9×	12 0.2×	3 0.1×	29	365
Ping Chong Bee Malaysia	12	151 0.8×	38 0.3×	84 1.0×	11 0.2×	6 0.1×	58	461
María Borrell Spain	9	130 0.7×	51 0.5×	41 0.5×	63 1.1×	3 0.1×	22	343
Alexander Tolios Austria	12	73 0.4×	75 0.7×	19 0.2×	30 0.5×	2 0.1×	38	513
Marzia Matucci Italy	14	231 1.2×	33 0.3×	52 0.6×	8 0.1×	14 0.3×	36	527
Joe Murphy United States	6	82 0.4×	89 0.8×	182 2.1×	62 1.1×	2 0.1×	8	395

Countries citing papers authored by Alexander Solms

Since Specialization

Citations

This map shows the geographic impact of Alexander Solms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Solms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Solms more than expected).

Fields of papers citing papers by Alexander Solms

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Solms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Solms. The network helps show where Alexander Solms may publish in the future.

Co-authorship network of co-authors of Alexander Solms

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Solms. A scholar is included among the top collaborators of Alexander Solms based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Solms. Alexander Solms is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Huijun, Kirstin Thelen, Frauke Friedrichs, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and Translational Science. 17(4). e13784–e13784. 7 indexed citations

Willmann, Stefan, Adam Lloyd, Rupert Austin, et al.. (2024). Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2137–2149. 1 indexed citations

Winkelmayer, Wolfgang C., Anthonie W.A. Lensing, Ravi Thadhani, et al.. (2024). A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International. 106(1). 145–153. 16 indexed citations

Reding, Mark T., Shadan Lalezari, Gili Kenet, et al.. (2024). Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review. Drugs in R&D. 24(3). 359–381. 3 indexed citations

Wellhagen, Gustaf J., Ashraf Yassen, Dirk Garmann, et al.. (2024). Evaluation of covariate effects in item response theory models. CPT Pharmacometrics & Systems Pharmacology. 13(5). 812–822. 2 indexed citations

Hilpert, Jan, Laura Bennett, Catriona L. K. Barnes, et al.. (2023). Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis. Drugs in R&D. 23(3). 221–237. 10 indexed citations

Goteti, Kosalaram, Mindy Magee, Sven Mensing, et al.. (2023). Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective. Clinical Pharmacology & Therapeutics. 114(2). 266–274. 5 indexed citations

Solms, Alexander, et al.. (2023). Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches. Clinical Pharmacokinetics. 62(11). 1639–1648. 1 indexed citations

Chen, Rong, J. Lister, Rong Han, et al.. (2022). Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting. BMC Medical Research Methodology. 22(1). 215–215.

10.

Willmann, Stefan, Alexander Solms, Markus Jensen, et al.. (2021). PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics & Systems Pharmacology. 10(8). 890–901. 36 indexed citations

11.

Berntorp, Erik, Cédric Hermans, Alexander Solms, Lone Hvitfeldt Poulsen, & Maria Elisa Mancuso. (2021). Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Reviews. 50. 100852–100852. 44 indexed citations

12.

Santoro, Cristina, Beng Fuh, Phu-Quoc Lê, et al.. (2020). BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. European Journal Of Haematology. 105(2). 164–172. 4 indexed citations

13.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 1–11. 4 indexed citations

14.

Solms, Alexander, Stefan Willmann, Theodore E. Spiro, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 50(1). 12–19. 11 indexed citations

15.

Zhang, Liping, Xiaoyu Yan, Keith A.A. Fox, et al.. (2020). Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 50(1). 20–29. 15 indexed citations

16.

Iorio, Alfonso, Monika Maas Enriquez, Heinz Delesen, et al.. (2019). Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. Blood. 134(Supplement_1). 3637–3637. 1 indexed citations

17.

Shah, Anita, Alexander Solms, Maurice J. Ahsman, et al.. (2019). Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology. 98(9). 2035–2044. 23 indexed citations

18.

Solms, Alexander, et al.. (2019). Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. Haematologica. 105(5). 1443–1453. 19 indexed citations

19.

Solms, Alexander, Henk‐Jan Drenth, Jordi Bruix, et al.. (2017). Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. European Journal of Pharmaceutical Sciences. 109. S149–S153. 18 indexed citations

20.

Shah, Anita, et al.. (2016). Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clinical Pharmacokinetics. 56(9). 1045–1055. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact